Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) just unveiled an update.
Qyuns Therapeutics has announced that the first subjects have been dosed in a Phase I clinical trial of QX030N/CLD-423, a bispecific antibody targeting IL-23p19 and TL1A, positioning the asset at the forefront of next-generation inflammatory bowel disease therapies as single-target drugs reach an efficacy ceiling. Under a global out-licensing agreement, its partner Caldera Therapeutics, which has secured cumulative funding of US$112.5 million from a roster of prominent biotech investors, is leading the development and commercialization of QX030N/CLD-423, underscoring strong external validation of the program and potentially strengthening Qyuns’ strategic role in the IBD treatment landscape.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$23.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative biologic therapies for immune-mediated and inflammatory diseases. Working with global partners, it advances antibody-based drug candidates aimed at conditions such as inflammatory bowel disease, targeting clinically validated pathways to improve treatment efficacy and safety.
Average Trading Volume: 493,134
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$5.04B
Find detailed analytics on 2509 stock on TipRanks’ Stock Analysis page.